PLIANT THERAPEUTICS INC
PLRXNASDAQTrading Snapshot
- Day Range
- $0.87 – $0.88
- 52-Week Range
- $0.83 – $1.83
- Volume (shares)
- 38,464.688
- Avg Volume (shares)
- —
- Shares Outstanding
- 61.9M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -0.6
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.49
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1.4%
PLIANT THERAPEUTICS INC
PLRX
StockOtter · stockotter.spaceAbout PLIANT THERAPEUTICS INC
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)
Recognized leader in RNAi drug discovery with track record of advancing novel delivery platforms and therapeutics to drive Company's integrin-mediated delivery platform
Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026
Features FORTIFY, the ongoing Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc.
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
Leader in targeted immuno-oncology drug development brings three decades of academic and biopharmaceutical oncology expertise
Reviewing Pliant Therapeutics (NASDAQ:PLRX) & Black Diamond Therapeutics (NASDAQ:BDTX)
Pliant Therapeutics (NASDAQ: PLRX - Get Free Report) and Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two compan
Connor Clark & Lunn Investment Management Ltd. Makes New $611,000 Investment in Pliant Therapeutics, Inc. $PLRX
Connor Clark and Lunn Investment Management Ltd. bought a new stake in Pliant Therapeutics, Inc. (NASDAQ: PLRX) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (S
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for PLN-10109